v3.26.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Concentration Risk [Line Items]          
Unbilled receivables $ 155,200   $ 155,200   $ 155,100
Rebate receivable 29,700   29,700   35,300
Investments in equity-method investees 30,200   30,200   $ 27,900
Equity in earnings of joint ventures $ 1,500 $ 2,200 4,916 $ 5,300  
Distributions received from the investees     $ 2,600 $ 2,100  
Revenue from Contract with Customer Benchmark | Governmental Healthcare Programs | Government Healthcare Programs          
Concentration Risk [Line Items]          
Concentration ​risk (as a percent) 13.00% 12.00% 13.00% 12.00%  
Accounts Receivable, Benchmark | Governmental Healthcare Programs | Government Healthcare Programs          
Concentration Risk [Line Items]          
Concentration ​risk (as a percent)     12.00%   13.00%
Cost of Goods and Service, Product and Service Benchmark | Medical Supply Vendors | Three Vendors          
Concentration Risk [Line Items]          
Concentration ​risk (as a percent) 55.00%   57.00%    
Cost of Goods and Service, Product and Service Benchmark | Medical Supply Vendors | Four Vendors          
Concentration Risk [Line Items]          
Concentration ​risk (as a percent)   66.00%   67.00%  
Largest Payer | Revenue from Contract with Customer Benchmark | Company's Largest Payer          
Concentration Risk [Line Items]          
Concentration ​risk (as a percent) 14.00% 14.00% 14.00% 14.00%  
Joint Venture          
Concentration Risk [Line Items]          
Distributions received from the investees $ 1,500 $ 500 $ 2,600 $ 2,100